Research Topics
| A LeizoroviczSummaryCountry: France Publications
| Collaborators
|
Detail Information
Publications
Heterogeneity prevails: the state of clinical trial data management in Europe - results of a survey of ECRIN centresWolfgang Kuchinke
Coordination Centre for Clinical Trials, Heinrich Heine University Duesseldorf, Duesseldorf, Germany
Trials 11:79. 2010....
Safety profile of tinzaparin versus subcutaneous unfractionated heparin in elderly patients with impaired renal function treated for acute deep vein thrombosis: the Innohep® in Renal Insufficiency Study (IRIS)Alain Leizorovicz
Faculte de Medecine Laennec, Service de Pharmacologie, Clinique, Rue Guillaume Paradin, 69008, Lyon, France
Thromb Res 128:27-34. 2011..IRIS aimed to assess whether LMWH is at least as safe as UFH in this population...
Epidemiology of post-operative venous thromboembolism in Asian patients. Results of the SMART venography studyAlain Leizorovicz
Service de Pharmacologie Clinique, EA 643, Universite de Lyon 1, Lyon, France
Haematologica 92:1194-200. 2007..The aim of this study was to estimate the rate of venous thromboembolism, including asymptomatic deep-vein thrombosis, undergoing hip or knee surgery and not receiving pharmacological thromboprophylaxis...- Epidemiology of venous thromboembolism in Asian patients undergoing major orthopedic surgery without thromboprophylaxis. The SMART studyA Leizorovicz
Service de Pharmacologie Clinique, EA 3736, Universite de Lyon 1, Lyon, France
J Thromb Haemost 3:28-34. 2005..In Asian patients undergoing surgery, the incidence of venous thromboembolism (VTE) is thought to be low relative to Western patients, and the routine use of thromboprophylaxis is controversial... - Preventing venous thromboembolism in medical patientsAlain Leizorovicz
Unite de Pharmacologie Clinique, EA 3736, Universite Claude Bernard Lyon I, Rue Guillaume Paradin, 69376 Lyon Cedex 08, France
Circulation 110:IV13-9. 2004..Based on duration of use in clinical trials in acutely ill medical patients, prophylactic treatment with UFH and LMWH is recommended for 2 weeks... - Randomized, placebo-controlled trial of dalteparin for the prevention of venous thromboembolism in acutely ill medical patientsAlain Leizorovicz
Unite de Pharmacologie Clinique, Universite Claude Bernard Lyon I, Lyon, France
Circulation 110:874-9. 2004.... - Bisoprolol for the treatment of chronic heart failure: a meta-analysis on individual data of two placebo-controlled studies--CIBIS and CIBIS II. Cardiac Insufficiency Bisoprolol StudyAlain Leizorovicz
Service de Pharmacologie Clinique, Universite Claude Bernard, Lyon, France
Am Heart J 143:301-7. 2002..This may help clinicians in their decisions as to whether to prescribe bisoprolol for their individual patients... - Coronary reperfusion rates in acute myocardial infarction patients after thrombolytic treatment with anistreplase: correlation with the delay from onset of symptoms to treatment: a review of 424 case records of patients admitted to coronary reperfusion stA Leizorovicz
Hôpital Neuro Cardiologique, Département Méthodologie et Essais Thérapeutiques, Lyon, France
J Cardiovasc Pharmacol 19:34-9. 1992..This may contribute to the lower mortality rate observed with early fibrinolytic treatment... - A randomised placebo-controlled pilot dose-response study with anisoylated plasminogen streptokinase activator complex in acute coronary artery occlusionsA Leizorovicz
Unite de Pharmacologie Clinique, Hôpital Neuro Cardiologique, Lyon
Drugs 33:133-7. 1987..The reperfusion rates were as follows: placebo, 0/9; APSAC 15U, 5/8; APSAC 20U, 5/9; APSAC 25U, 6/9; APSAC 30U, 5/9. Reperfusion was achieved in 60% of treated patients but no dose relationship was revealed... - EasyMA: a program for the meta-analysis of clinical trialsM Cucherat
Service de Pharmacologie Clinique, Hopital Cardiologique, Lyon, France
Comput Methods Programs Biomed 53:187-90. 1997..Data-editing and data-manipulating facilities are also possible. Much care has been taken to make the user interface as user-friendly as possible, so that the program is within the reach of all medical researchers... - New insights on the relation between untreated and treated outcomes for a given therapy effect model is not necessarily linearJean Pierre Boissel
Institute for Theoretical Medicine and CNRS UMR5558, RTH Laennec School of Medicine, Rue Guillaume Paradin, 69008 Lyon, France
J Clin Epidemiol 61:301-7. 2008..We have called this relation the effect model. Our objectives were to demonstrate that the relation is general and not necessarily linear... - A systematic review of the accuracy of ultrasound in the diagnosis of deep venous thrombosis in asymptomatic patientsBehrouz Kassai
Clinical Pharmacology Unit, Rue Guillaume Paradin BP8071 69376, Lyon Cedex 08, France
Thromb Haemost 91:655-66. 2004..Our results suggest that, particularly for proximal veins, ultrasound is accurate for the diagnosis of DVT in asymptomatic postoperative orthopedic patients. More research is needed in other clinical settings... - Ventricular fibrillation following administration of thrombolytic treatment. The EMIP experience. European Myocardial Infarction ProjectJ P Boissel
Service de Pharmacologie Clinique, Lyon, France
Eur Heart J 17:213-21. 1996..These results suggest the existence of reperfusion-induced ventricular fibrillation in patients developing myocardial infarction who receive thrombolytic treatment... - The assessment of deep vein thromboses for therapeutic trialsAlain Leizorovicz
Clinical Pharmacology Department, University Claude Bernard, , Rue Guillaume Paradin, Lyon, France
Angiology 54:19-24. 2003..Compression ultrasonography has already been adopted as the principal method for evaluating DVT in several ongoing large scale prevention trials with the approval of major drug agencies... - QT dynamicity and sudden death after myocardial infarction: results of a long-term follow-up studyPhilippe Chevalier
Hopital Louis Pradel, Lyon, France
J Cardiovasc Electrophysiol 14:227-33. 2003..The aim of this study was to determine whether impaired adaptation of the QT interval to changes in heart rate predicts sudden death after an acute myocardial infarction... - Influence of age on the prescription of vitamin K antagonists in outpatients with permanent atrial fibrillation in FranceA Leizorovicz
Service de Pharmacologie Clinique, EA 3736, Faculté R T H Laennec, Universite Lyon 1, Rue Guillaume Paradin, BP 8071 69376 LYON cedex 08, France
Pharmacoepidemiol Drug Saf 16:32-8. 2007.... - Primary angioplasty versus prehospital fibrinolysis in acute myocardial infarction: a randomised studyEric Bonnefoy
Coronary Care Unit, , Hospices Civils de Lyon, Lyon, France
Lancet 360:825-9. 2002.... - Correlation of plasma coagulation parameters with thromboprophylaxis, patient characteristics, and outcome in the MEDENOX studyLouis Desjardins
Service hématologie, CHU Laval, Ste Foy, Quebec, Canada
Arch Pathol Lab Med 128:519-26. 2004..Plasma anti-Xa and anti-IIa activities correlate with the dose of low-molecular-weight heparin, and D-dimer and thrombin-antithrombin complexes are markers of procoagulant activity... - Risk factors for venous thromboembolism in hospitalized patients with acute medical illness: analysis of the MEDENOX StudyRaza Alikhan
Academic Department of Surgery, Guy's, King's, and St Thomas' School of Medicine, London, England
Arch Intern Med 164:963-8. 2004..These findings allow recognition of individuals at increased risk of VTE and will contribute to the formulation of an evidence-based risk assessment model for thromboprophylaxis in hospitalized general medical patients... - Prevention of venous thromboembolism in medical patients with enoxaparin: a subgroup analysis of the MEDENOX studyRaza Alikhan
Academic Department of Surgery, Guy's, King's, St Thomas' School of Medicine, London, UK
Blood Coagul Fibrinolysis 14:341-6. 2003..22 (95% CI, 0.09-0.51); immobility, 0.53 (95% CI, 0.14-1.72); previous VTE, 0.49 (95% CI, 0.15-1.68); and cancer, 0.50 (95%o CI, 0.14-1.72). The beneficial effects of enoxaparin extend to a wide range of acutely ill medical patients... - Factors predictive of venous thrombotic complications in patients with isolated superficial vein thrombosisSara Quenet
Clinical Pharmacology Department, University Hospital Bellevue, Saint Etienne, France
J Vasc Surg 38:944-9. 2003..Superficial vein thrombosis may be complicated with venous thromboembolism. We examined factors predictive of venous thromboembolism in superficial vein thrombosis, which, to our knowledge, had not been prospectively studied before... - Thromboprophylaxis with dalteparin in medical patients: which patients benefit?Alexander T Cohen
Department of Surgery, King s College Hospital, Bessemer Road, London SE5 9PJ, UK
Vasc Med 12:123-7. 2007..Our findings, therefore, support the broad application of thromboprophylaxis in acutely ill hospitalized medical patients... - Prevention of venous thromboembolism in medically ill patients: a clinical updateAlexander G G Turpie
Department of Medicine, Hamilton General Hospital, HHS McMaster Clinic, 237 Barton Street East, Hamilton, Ontario L8L 2X2, Canada
Postgrad Med J 82:806-9. 2006.... - Mortality rates and risk factors for asymptomatic deep vein thrombosis in medical patientsPaul T Vaitkus
Cardiology Division, College of Medicine, University of Illinois at Chicago, 840 S Wood St, Chicago, Illinois 60612, USA
Thromb Haemost 93:76-9. 2005..In conclusion, the high mortality rate in patients with asymptomatic proximal DVT underscores its clinical relevance and supports targeting of asymptomatic proximal DVT as an appropriate endpoint in clinical trials of thromboprophylaxis... - Efficacy and safety of fixed low-dose dalteparin in preventing venous thromboembolism among obese or elderly hospitalized patients: a subgroup analysis of the PREVENT trialNils Kucher
Cardiovascular Division, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA
Arch Intern Med 165:341-5. 2005..99) and in elderly (1.1% vs 0.7%; P=.12) patients. CONCLUSION: Our findings suggest that a fixed low dose of dalteparin sodium of 5000 U/d is effective and safe in preventing VTE in obese and elderly hospitalized medical patients... - Impact of time to treatment on mortality after prehospital fibrinolysis or primary angioplasty: data from the CAPTIM randomized clinical trialPhilippe Gabriel Steg
Service de cardiologie, Hopital Bichat, 46 rue Henri Huchard, 75877 Paris Cedex 18, France
Circulation 108:2851-6. 2003.... - Predictors of cardiovascular events in patients with end-stage renal disease: an analysis from the Fosinopril in dialysis studyMichele Kessler
Department of Nephrology, University Hospital of Nancy, Nancy, France
Nephrol Dial Transplant 22:3573-9. 2007..A risk prediction model was created from the FOSIDIAL trial to identify factors predictive of CVE and to evaluate the relative strength of known predictors when considered together in a multivariate model... - Prognosis of patients with atherothrombotic disease: a prospective survey in a non-hospital settingJean Ferrieres
INSERM U 558, Department of Epidemiology, Toulouse, France
Int J Cardiol 112:302-7. 2006..However, atherothrombotic diseases are often associated and little is known of the prognosis of these diseases taken as a whole... - Antithrombotic management after an ischemic stroke in French primary care practice: results from three pooled cross-sectional studiesEmmanuel Touze
Department of Neurology, Hopital Sainte Anne, René Descartes, Paris, France
Cerebrovasc Dis 20:78-84. 2005..We aimed at quantifying and explaining the underuse of antithrombotic treatments after an ischemic stroke in patients seen in French primary care... - Primary angioplasty is cost-minimizing compared with pre-hospital thrombolysis for patients within 60 min of a percutaneous coronary intervention center: the Comparison of Angioplasty and Pre-hospital Thrombolysis in Acute Myocardial Infarction (CAPTIM) cJacques Machecourt
Coronary Care Unit, CHU Grenoble, Grenoble, France
J Am Coll Cardiol 45:515-24. 2005....